Elias Altrabsheh

Placeholder Person Graphic
D-fine
Model Developer
Elias Altrabsheh started his career as a model developer working on health economics models in multiple therapeutic areas such as diabetes and infectious diseases. Since then, he has evaluated digital health therapeutic and technical projects concerned with developing ML/analytics/software
as a service platforms in the health care space. Currently, at d-fine as Consultant, Elias applies his technical expertise to projects involving modeling and software development and is active within the pharmaceutical/health care community. Elias obtained an MSc in complex systems modeling at King’s College London.

Related Articles

The Road to Explainable AI in GXP-Regulated Areas
Features
The Road to Explainable AI in GXP-Regulated Areas

Recent advances in artificial intelligence (AI) have led to its widespread industrial adoption, with machine learning (ML) algorithms demonstrating advances in performance in a wide range of tasks. However, this comes with an ever-increasing complexity of the algorithms used, rendering such systems more difficult to explain.1

  • 1Samek, W., and K. R. Müller. “Towards Explainable...
Figure 3: Overview of AI application fields in the pharmaceutical production process and value chain.
Technical
AI Governance and QA Framework: AI Governance Process Design

Artificial intelligence (AI) has the potential to benefit the pharmaceutical industry and its GxP-regulated areas. Several pharmaceutical companies are currently running digital pilots; 90% of large pharmaceutical companies have initiated AI projects.1

  • 1Trinity Life Sciences. “Ninety Percent of Large Pharma Companies Initiated Artificial Intelligence/Machine Learning Projects In...